551 results on '"Cooper, D L"'
Search Results
2. An eco-profile of building materials
3. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
4. Can syndromic thresholds provide early warning of national influenza outbreaks?
5. Linking Syndromic Surveillance with Virological Self-Sampling
6. Use of Pseudo-Observability Indices In Identification of Continuous-Time Multivariable Models
7. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry
8. Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant
9. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population
10. Impact of haemophilia with inhibitors on caregiver burden in the United States
11. Long-term outcomes from orthopaedic surgery in haemophilia: are we measuring success and documenting and assessing complications?
12. Haemophilia Experiences, Results and Opportunities (HERO) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia
13. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States
14. Use of recombinant activated factor VII in patients with Glanzmannʼs thrombasthenia: a review of the literature
15. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries
16. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics
17. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents
18. Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma
19. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE)
20. Health-related quality of life in haemophilia patients with inhibitors and their caregivers
21. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004–2008)
22. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres
23. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients
24. Late Onset Alloimmune Extravascular Hemolysis Mediated by Donor-Derived Lymphocytes Following Allogeneic Stem Cell Transplantation: S71-030K
25. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE)
26. Patient/Caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)
27. U.S. survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors
28. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A
29. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg−1 in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004–2008)
30. Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX
31. Re: Discordant pair analysis of rFVIIa and pd-aPCC response
32. Modern Valence Bond Theory
33. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004–2008)
34. Spin-orbit coupling effects in diatomic molecules
35. Altered Fcc receptor (FccR) expression on monocyte subsets in rheumatoid arthritis: 20.4
36. Cisplatin, Fluorouracil, and Leucovorin Induction Chemotherapy Followed by Concurrent Cisplatin Chemoradiotherapy for Organ Preservation and Cure in Patients With Advanced Head and Neck Cancer: Long-Term Follow-Up
37. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
38. Prognostic significance of CD44 expression in adenocarcinoma of the lung
39. Recombinant activated factor VII in approved indications: Update on safety
40. Impact of pain and functional impairment in US adults with haemophilia: Patient-reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P-FiQ) study
41. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study
42. Mutual neutralization and chemiionization in collisions of alkali metal and halogen atoms.
43. Spectrum and decay of the doubly charged water ion.
44. Ionic solids at high pressures and elevated temperatures: MgO (periclase).
45. Temocillin Concentrations in Human Tissues
46. Impact of pain and functional impairment in US adults with haemophilia: Patient‐reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (P‐FiQ) study.
47. US experience with recombinant factor VIIa for surgery and other invasive procedures in acquired haemophilia: analysis from the Hemostasis and Thrombosis Research Society Registry
48. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
49. Surveillance for Health Protection in England and Wales: An analysis of NHS Direct syndromic data
50. Preliminary report on the Oldenburg “butter shale” in the Upper Ordovician (Katian; Richmondian) Waynesville Formation, USA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.